TG Therapeutics

TGTX NASDAQ
6.84
+0.29
+4.43%
盘后: 6.84 0 0.00% 17:58 08/16 EDT
开盘
6.60
昨收
6.55
最高
6.91
最低
6.56
成交量
91.91万
成交均量(3M)
135.90万
52周最高
12.90
52周最低
3.320
换手率
0.97%
市值
6.48亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供TG Therapeutics TGTX股票价格,TG Therapeutics股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti- programmed cell death ligand 1 (PD-L1) and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies.
展开 >

最近浏览

名称
价格
涨跌幅